Skip to main content

Table 3 Multivariate analysis of factors determining outcomes at 2 years

From: Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT

N = 2156

RI

NRM

LFS

OS

GRFS

Acute GVHD II-IV

Acute GVHD III-IV

Chronic GVHD

Extensive cGVHD

HR (95% CI)

P

HR (95% CI)

P

HR (95% CI)

P

HR (95% CI)

P

HR (95% CI)

P

HR (95% CI)

P

HR (95% CI)

P

HR (95% CI)

P

HR (95% CI)

P

MRD pos vs neg

1.51 (1.26–1.80)

< 0.001

0.99 (0.80–1.23)

0.928

1.26 (1.10–1.44)

0.001

1.19 (1.02–1.39)

0.028

1.25 (1.10–1.41)

< 0.001

1.12 (0.96–1.32)

0.161

1.09 (0.80–1.48)

0.585

1.00 (0.85–1.18)

0.996

0.99 (0.79–1.24)

0.949

Ph neg B-ALL

1

–

1

–

1

–

1

–

1

–

1

–

1

–

1

–

1

–

Ph pos B-ALL

0.94 (0.75–1.18)

0.609

1.43 (1.07–1.91)

0.015

1.12 (0.94–1.33)

0.198

0.94 (0.72–1.14)

0.531

1.02 (0.87–1.19)

0.818

0.96 (0.79–1.17)

0.663

0.87 (0.61–1.25)

0.456

0.95 (0.78–1.16)

0.637

1.08 (0.82–1.42)

0.578

T-ALL

1.11 (0.86–1.43)

0.445

1.11 (0.78–1.58)

0.554

1.13 (0.92–1.39)

0.246

1.06 (0.85–1.33)

0.611

1.03 (0.86–1.25)

0.720

1.10 (0.87–1.39)

0.429

0.84 (0.54–1.30)

0.440

0.84 (0.66–1.06)

0.138

1.01 (0.73–1.41)

0.938

Age (per 10 years)

1.03 (0.96–1.11)

0.369

1.32 (1.22–1.42)

< 0.001

1.15 (1.09–1.21)

< 0.001

1.21 (1.14–1.28)

< 0.001

1.12 (1.06–1.18)

< 0.001

1.08 (1.01–1.15)

0.019

1.09 (0.97–1.22)

0.170

1.07 (1.01–1.14)

0.025

1.06 (0.97–1.15)

0.218

Year of HCT

0.97 (0.95–0.99)

0.042

0.97 (0.94–1.00)

0.053

0.97 (0.95–0.99)

0.005

0.98 (0.95–0.10)

0.030

0.99 (0.97–1.00)

0.096

0.98 (0.96–0.10)

0.032

0.97 (0.93–1.01)

0.173

0.97 (0.94–0.99)

0.002

1.01 (0.98–1.04)

0.628

CR2 vs CR1

2.29 (1.83–2.88)

< 0.001

1.63 (1.2–2.23)

0.002

2.02 (1.68–2.42)

< 0.001

2.11 (1.72–2.59)

< 0.001

1.70 (1.43–2.03)

< 0.001

1.21 (0.97–1.52)

0.096

1.58 (1.06–2.36)

0.025

1.07 (0.82–1.40)

0.604

1.19 (0.82–1.73)

0.358

KPS > =90%

1.09 (0.88–1.35)

0.418

1.14 (0.89–1.47)

0.297

1.12 (0.95–1.31)

0.173

1.01 (0.85–1.21)

0.896

1.03 (0.90–1.19)

0.648

0.98 (0.82–1.18)

0.839

0.97 (0.69–1.36)

0.841

1.02 (0.85–1.22)

0.826

1.08 (0.84–1.39)

0.543

UD 10/10

0.66 (0.52–0.83)

< 0.001

1.91 (1.45–2.51)

< 0.001

1.02 (0.86–1.22)

0.793

1.24 (1.01–1.51)

0.038

1.14 (0.97–1.34)

0.125

1.66 (1.35–2.05)

< 0.001

2.02 (1.38–2.95)

< 0.001

1.39 (1.14–1.70)

0.001

1.26 (0.96–1.66)

0.099

UD 9/10

0.57 (0.42–0.81)

0.001

2.10 (1.49–2.98)

< 0.001

1.01 (0.80–1.27)

0.942

1.31 (1.01–1.69)

0.043

1.02 (0.82–1.26)

0.876

1.73 (1.33–2.26)

< 0.001

1.75 (1.04–2.94)

0.035

1.32 (1.01–1.73)

0.042

1.07 (0.73–1.59)

0.716

Blood vs BM

0.90 (0.73–1.10)

0.288

1.07 (0.83–1.38)

0.607

0.95 (0.82–1.11)

0.534

0.39 (0.77–1.12)

0.432

1.17 (1.01–1.36)

0.043

1.08 (0.88–1.33)

0.450

1.14 (0.79–1.65)

0.496

1.44 (1.18–1.76)

< 0.001

1.83 (1.37–2.45)

< 0.001

Female vs male

0.80 (0.67–0.96)

0.018

0.93 (0.75–1.16)

0.531

0.86 (0.75–0.99)

0.031

0.86 (0.74–1.01)

0.062

0.88 (0.77–0.99)

0.039

0.94 (0.80–1.11)

0.466

0.73 (0.53–0.10)

0.047

0.92 (0.79–1.08)

0.294

0.91 (0.73–1.14)

0.411

Donor fem vs male

0.66 (0.55–0.80)

< 0.001

1.29 (1.05–1.60)

0.018

0.89 (0.77–1.02)

0.098

0.97 (0.83–1.13)

0.671

0.96 (0.85–1.09)

0.519

1.11 (0.94–1.30)

0.209

1.00 (0.73–1.37)

0.986

1.33 (1.13–1.55)

< 0.001

1.23 (0.99–1.53)

0.0593

Pt CMV pos vs neg

0.93 (0.76–1.13)

0.447

1.23 (0.98–1.56)

0.081

1.06 (0.91–1.23)

0.462

1.24 (1.05–1.47)

0.014

1.02 (0.89–1.17)

0.784

0.96 (0.80–1.13)

0.603

1.01 (0.73–1.41)

0.943

0.10 (0.84–1.19)

0.972

1.04 (0.81–1.32)

0.780

Dr CMV pos vs neg

1.12 (0.92–1.36)

0.276

0.89 (0.71–1.11)

0.300

0.99 (0.86–1.15)

0.931

0.95 (0.81–1.12)

0.548

1.07 (0.94–1.23)

0.315

1.08 (0.91–1.28)

0.364

1.11 (0.80–1.54)

0.523

1.18 (1.00–1.40)

0.0567

1.30 (1.02–1.65)

0.036

TBI vs chemo

0.60 (0.49–0.74)

< 0.001

0.87 (0.68–1.12)

0.292

0.70 (0.60–0.82)

< 0.001

0.75 (0.62–0.90)

0.002

0.88 (0.76–1.03)

0.104

1.18 (0.95–1.46)

0.126

1.02 (0.69–1.51)

0.922

1.23 (0.99–1.52)

0.0647

1.27 (0.93–1.75)

0.131

In vivo TCD vs no TCD

1.22 (0.97–1.53)

0.090

0.68 (0.52–0.88)

0.004

0.94 (0.79–1.12)

0.494

0.84 (0.69–1.02)

0.077

0.75 (0.64–0.88)

< 0.001

0.72 (0.59–0.89)

0.002

0.51 (0.33–0.75)

< 0.001

0.58 (0.47–0.71)

< 0.001

0.48 (0.36–0.64)

< 0.001

Center (frailty)

–

0.314

–

0.17

–

0.295

–

0.015

–

0.019

–

< 0.001

–

< 0.001

–

0.028

–

0.004

  1. Abbreviations: BM bone marrow, CR complete remission, CMV cytomegalovirus, dr donor, GVHD graft-versus-host disease, GRFS GVHD-free and relapse-free survival, HCT hematopoietic cell transplantation, KPS Karnofsky performance score, LFS leukemia-free survival, MRD measurable residual disease, NRM non-relapse mortality, OS overall survival, Ph Philadelphia chromosome/BCR-ABL gene rearrangement, pt patient, RI relapse incidence, TCD T cell depletion, UD unrelated donor
Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us